摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyric acid | 58898-49-0

中文名称
——
中文别名
——
英文名称
4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyric acid
英文别名
6-(3'-carboxy)-propoxy-3,4-dihydrocarbostyril;4-(-3,4-dihydro-6-carbostyriloxy)butyric acid;4-[(2-Oxo-1,2,3,4-tetrahydroquinolin-6-yl)oxy]butanoic acid;4-[(2-oxo-3,4-dihydro-1H-quinolin-6-yl)oxy]butanoic acid
4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyric acid化学式
CAS
58898-49-0
化学式
C13H15NO4
mdl
MFCD09814610
分子量
249.266
InChiKey
LHSYLPPPCKSEOW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    218-220 °C(Solv: ethanol (64-17-5))
  • 沸点:
    549.7±50.0 °C(Predicted)
  • 密度:
    1.265±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.384
  • 拓扑面积:
    75.6
  • 氢给体数:
    2
  • 氢受体数:
    4

SDS

SDS:a991ce6ad7361658663caabc8c8de165
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyric acid2,3-二氯-5,6-二氰基-1,4-苯醌 作用下, 以 1,4-二氧六环 为溶剂, 反应 15.0h, 以85%的产率得到4-[(2-氧代-1H-喹啉-6-基)氧基]丁酸
    参考文献:
    名称:
    2-氧代喹啉衍生物作为血小板聚集抑制剂的研究。I.4-(2-氧代-1,2,3,4-四氢-6-喹啉基氧基)丁酸酯和相关化合物。
    摘要:
    合成并测试了许多烷基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯及相关化合物对体外血小板聚集的抑制活性。其中,乙基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯显示出最强的抑制活性。讨论了构效关系。
    DOI:
    10.1248/cpb.31.798
  • 作为产物:
    描述:
    ethyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyratesodium hydroxide 作用下, 以 甲醇 为溶剂, 反应 1.5h, 以87.4%的产率得到4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyric acid
    参考文献:
    名称:
    2-氧代喹啉衍生物作为血小板聚集抑制剂的研究。I.4-(2-氧代-1,2,3,4-四氢-6-喹啉基氧基)丁酸酯和相关化合物。
    摘要:
    合成并测试了许多烷基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯及相关化合物对体外血小板聚集的抑制活性。其中,乙基4-(2-氧代-1, 2, 3, 4-四氢-6-喹啉氧基)丁酸酯显示出最强的抑制活性。讨论了构效关系。
    DOI:
    10.1248/cpb.31.798
点击查看最新优质反应信息

文献信息

  • Carbostyril derivatives
    申请人:Otsuka Pharmaceutical Co., Ltd.
    公开号:US04435404A1
    公开(公告)日:1984-03-06
    Novel carbostyril derivative and its salt represented by the general formula (1), ##STR1## wherein R.sup.1 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a phenyl-lower alkyl group; R.sup.2 is a hydrogen atom, a lower alkyl group or a group of the formula ##STR2## wherein A is a lower alkylene group; R.sup.3 is a lower alkyl group, a hydroxy lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkanoyloxy-lower alkyl group or a benzoyloxy-lower alkyl group; and R.sup.4 is a C.sub.3-10 -cycloalkyl group which may have at least one hydroxyl group as the substituent(s) in the cycloalkyl ring, a C.sub.3-10 -cycloalkyl-lower alkyl group, a phenyl group, a phenyl-lower alkyl group which may have at least one lower alkoxy group as the substituent(s) in the phenyl ring, a lower alkyl group which may have at least one hydroxyl group as the substituent(s), a heterocyclic ring residue or a lower alkyl group having one heterocyclic ring residue as the substituent; further, R.sup.3, R.sup.4 and the adjacent nitrogen atom, as well as with or without another nitrogen atom, may form a group of the formula ##STR3## (wherein R.sup.5 is a phenyl group, a C.sub.3-10 -cycloalkyl group or a phenyl-lower alkyl group; and B is a methine group or a nitrogen atom); the carbon-carbon bond between the 3- and 4-positions in the carbostyril skeleton is a single or double bond; the substituted position of the group of the formula ##STR4## is any one of 5-, 6-, 7- or 8-position in the carbostyril skeleton; when the group of the formula ##STR5## is substituted at 5-, 6-, 7- or 8-position in the carbostyril skeleton, then R.sup.2 is a hydrogen atom or a lower alkyl group; alternatively, when R.sup.2 is a group of the formula ##STR6## then 5-, 6-, 7- and 8-positions in the carbostyril skeleton are hydrogen atoms and are not substituted with groups of the formula ##STR7## and when R.sup.3 is a lower alkyl group, then R.sup.4 should be neither of a C.sub.3-10 -cycloalkyl group, a C.sub.3-10 -cycloalkyl-lower alkyl group nor a lower alkyl group, having effects for preventing and treating thrombosis and embolism.
    新型的羧基喹啉衍生物及其盐由通式(1)表示,其中R.sup.1是氢原子,低碳基团,低烯基团或苯基-低碳基团;R.sup.2是氢原子,低碳基团或式##STR2##的基团,其中A是低碳烷基团;R.sup.3是低碳基团,羟基低碳基团,低烷氧基-低碳基团,低烷酰氧基-低碳基团或苯甲酰氧基-低碳基团;R.sup.4是C.sub.3-10-环烷基团,该环烷基团可能至少有一个羟基作为环烷基环上的取代基,C.sub.3-10-环烷基-低碳基团,苯基,苯基-低碳基团,该苯基环上可能至少有一个低烷氧基作为取代基,低碳基,该低碳基可能至少有一个羟基作为取代基,杂环环残基或具有一个杂环环残基作为取代基的低碳基;此外,R.sup.3,R.sup.4和相邻的氮原子,以及有或没有另一个氮原子,可能形成式##STR3##的基团(其中R.sup.5是苯基,C.sub.3-10-环烷基团或苯基-低碳基团;B是亚甲基基团或氮原子);羧基喹啉骨架中3-和4-位置之间的碳-碳键是单键或双键;式##STR4##的基团的取代位置是羧基喹啉骨架中的5-,6-,7-或8-位置中的任意一个;当式##STR5##的基团在羧基喹啉骨架的5-,6-,7-或8-位置取代时,R.sup.2是氢原子或低碳基团;或者,当R.sup.2是式##STR6##的基团时,羧基喹啉骨架的5-,6-,7-和8-位置是氢原子,并且未被式##STR7##的基团取代;当R.sup.3是低碳基团时,R.sup.4不应是C.sub.3-10-环烷基团,C.sub.3-10-环烷基-低碳基团或低碳基团,具有预防和治疗血栓形成和栓塞的作用。
  • Platelet aggregation inhibiting carbostyrils, their compositions and
    申请人:Otsuka Pharmaceutical Co., Ltd.
    公开号:US04070470A1
    公开(公告)日:1978-01-24
    Novel benzcycloamide derivatives represented by the general formula, ##STR1## wherein R.sub.1 is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or aralkyl; B is --CH.sub.2 --, --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--; A is ##STR2## (wherein R.sub.2 and R.sub.3 may be the same or different and are respectively hydrogen or C.sub.1-4 alkyl) or --CH.dbd.CH--; R.sub.4 is --OR.sub.5 (wherein R.sub.5 is hydrogen, C.sub.1-8 alkyl, cycloalkyl or aralkyl) or ##STR3## (wherein R.sub.6 and R.sub.7 may be the same or different and are respectively hydrogen, C.sub.1-4 alkyl or aralkyl or may form together with the nitrogen atom a 5- or 6-membered heterocyclic group which may further contain a nitrogen, oxygen or sulfur atom); and m and n each are zero or a positive integer and m + n is no more than 11. The benzcycloamide derivatives represented by the above-mentioned general formula (I) have excellent effects of inhibiting platelet aggregation and are useful as preventives for thrombosis and embolism.
    通用公式表示的新型苯环酰胺衍生物,其中R.sub.1为氢、C.sub.1-4烷基、C.sub.2-4烯基或芳基;B为--CH.sub.2 --、--CH.sub.2 --CH.sub.2 --或--CH.dbd.CH--;A为##STR2##(其中R.sub.2和R.sub.3可以相同也可以不同,分别为氢或C.sub.1-4烷基)或--CH.dbd.CH--;R.sub.4为--OR.sub.5(其中R.sub.5为氢、C.sub.1-8烷基、环烷基或芳基)或##STR3##(其中R.sub.6和R.sub.7可以相同也可以不同,分别为氢、C.sub.1-4烷基或芳基,或者与氮原子一起形成一个含氮、氧或硫原子的5-或6元杂环基);m和n各自为零或正整数,且m + n不超过11。上述通用公式(I)表示的苯环酰胺衍生物具有优异的抑制血小板聚集作用,并可用作预防血栓形成和栓塞的药物。
  • Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. III. N-Cyclohexyl-N-(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide and related compounds.
    作者:TAKAO NISHI、FUJIO TABUSA、TATSUYOSHI TANAKA、HIRAKI UEDA、TAKEFUMI SHIMIZU、TOSHIMI KANBE、YUKIO KIMURA、KAZUYUKI NAKAGAWA
    DOI:10.1248/cpb.31.852
    日期:——
    A series of N, N-disubstituted-ω-(1, 2-dihydro-2-oxoquinolyloxy) alkanecarboxamides was synthesized and tested for inhibitory activity towards collagen- and ADP-induced aggregation of rabbit blood platelet in vitro. These compounds were prepared by the reaction of ω-(1, 2-dihydro-2-oxoquinolyloxy) alkanoic acid and various amines by the mixed anhydride method. Among them, N-cyclohexyl-N-(2-hydroxyethyl)-4-(1, 2-dihydro-2-oxo-6-quinolyloxy) butyramide (IVa1) was found to have the most potent inhibitory activity. The structure-activity relationships are discussed.
    合成了一系列 N,N-取代的ω-(1, 2-二氢-2-氧羟喹啉氧基)烷基氨基酸酰胺,并对其在体外对胶原和ADP诱导的兔血小板聚集的抑制活性进行了测试。这些化合物是通过ω-(1, 2-二氢-2-氧羟喹啉氧基)烷酸与各种胺反应,采用混合酸酐法制备的。其中,N-环己基-N-(2-羟乙基)-4-(1, 2-二氢-2-氧-6-喹啉氧基)丁酰胺(IVa1)被发现具有最强的抑制活性。文中讨论了结构-活性关系。
  • Novel carbostyril derivatives
    申请人:Otsuka Pharmaceutical Co., Ltd.
    公开号:US04298739A1
    公开(公告)日:1981-11-03
    Novel carbostyril derivatives having platelet aggregation inhibitory action, antiinflamatory action, antiulcer action, vasodilatory action and phosphodiesterase inhibitory action and are useful for preventing or curing thrombus, arteriosclerosis, hypertension, asthma and other like diseases, and also useful as an antiinflamatory or anti-ulcer agent, represented by the formula ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, phenyl-C.sub.1-4 alkyl-; R.sup.2 is hydrogen, a halogen atom, hydroxy, phenyl-C.sub.1-4 alkoxy; R.sup.3 is hydrogen, hydroxy, C.sub.1-4 alkyl; R.sup.4 is C.sub.3-8 cycloalkyl, substituted or unsubstituted phenyl, C.sub.3-8 cycloalkyl-C.sub.1-4 alkyl, 2-(3,4-dimethoxyphenyl)-ethyl, R.sup.5 is hydrogen, C.sub.1-8 alkyl, C.sub.2-4 alkenyl, phenyl, C.sub.3-8 cycloalkyl, phenyl-C.sub.1-4 alkyl, C.sub.3-8 cycloalkyl-C.sub.1-4 alkyl, m is an integer of 1 - 3, l and n which may be same or different, and are respectively 0 or an integer of 1 - 7 and the sum of l and n is not exceeding 7, the carbon-carbon bond at 3- and 4-positions in the carbostyril skelton is either single or double bond.
    具有抗血小板聚集抑制作用、抗炎作用、抗溃疡作用、扩血管作用和磷酸二酯酶抑制作用的新型羧基吲哚衍生物,用于预防或治疗血栓、动脉硬化、高血压、哮喘等疾病,同时也可用作抗炎或抗溃疡剂,其结构式如下:其中R.sup.1为氢、C.sub.1-4烷基、C.sub.2-4烯基、苯基-C.sub.1-4烷基-;R.sup.2为氢、卤素原子、羟基、苯基-C.sub.1-4烷氧基;R.sup.3为氢、羟基、C.sub.1-4烷基;R.sup.4为C.sub.3-8环烷基、取代或未取代苯基、C.sub.3-8环烷基-C.sub.1-4烷基、2-(3,4-二甲氧基苯基)-乙基;R.sup.5为氢、C.sub.1-8烷基、C.sub.2-4烯基、苯基、C.sub.3-8环烷基、苯基-C.sub.1-4烷基、C.sub.3-8环烷基-C.sub.1-4烷基;m为1-3的整数,l和n可以相同也可以不同,分别为0或1-7的整数,且l和n的和不超过7,在羧基吲哚骨架的3-和4-位置的碳-碳键为单键或双键。
  • NAKAGAWA, KAZUYUKI;UCHIDA, MINORU;OKA, KIMIAKI
    作者:NAKAGAWA, KAZUYUKI、UCHIDA, MINORU、OKA, KIMIAKI
    DOI:——
    日期:——
查看更多